Advertisement

Will These 3 Potential Blockbuster Drugs Lift Bristol Myers Squibb?

Will These 3 Potential Blockbuster Drugs Lift Bristol Myers Squibb?

Shares in pharmaceutical company Bristol Myers Squibb (NYSE: BMY) are up a little more than 11% over the past year. The company posted third-quarter revenue of $11.2 billion, a decrease of 3%, with one culprit being the loss of exclusivity for one of its blockbuster drugs, Revlimid. The blood cancer therapy reported sales of $2.4 billion, down 28% year over year.